Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension

You may not be if

• 2. Women of childbearing potential with negative urine pregnancy test (UPT) at all visits
• 1. Patients may not enter the OLE if they voluntarily withdrew from RCT or RW study or if the time period between participation exceeds 3 months
• 2. Evidence or history of malignancy
• 3. Evidence of invasive or life-threatening infection
• 4. History of tuberculosis
• 5. Life-threatening bleeding within 2 weeks of screening
• 6. Vaccination with a live vaccine within the previous 3 months
• 7. Evidence of severe organ compromise including but not limited to: (see details in the protocol)
• 8. Pregnant or breastfeeding females
• 9. Inability to follow highly effective birth control recommendations during the study and until 1 month after the end of the treatment.
• 10. Inability to provide informed consent, and also assent if applicable
• 11. Life expectancy less than 4 weeks
• 12. Concomitant use of other immunosuppression except NSAIDs, glucocorticoids, cyclosporine, tacrolimus, IL-1 inhibitors (Anakinra, Canakinumab, or Rilonacept)